<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01487499</url>
  </required_header>
  <id_info>
    <org_study_id>SCLC</org_study_id>
    <nct_id>NCT01487499</nct_id>
  </id_info>
  <brief_title>Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer (SCLC)</brief_title>
  <acronym>SCLC</acronym>
  <official_title>Bronchoscopic Intratumoral Chemotherapy for Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Florida</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project proposes to use bronchoscopic intratumoral chemotherapy for small cell lung
      cancer in two fashions:

        1. to implement a prospective clinical trial to test the feasibility and efficacy of
           intralesional chemotherapy as consolidative therapy immediately following standard
           systemic chemotherapy and radiation therapy for patients with limited stage SCLC by
           comparing tumor growth and survival rates of the treatment group and compare the
           outcomes to historical controls

        2. to implement a prospective clinical trial to test the feasibility and efficacy as
           measured by tumor growth and survival rates of intralesional chemotherapy for patients
           with recurrent SCLC after standard treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will receive standard of care treatment for SCLC with added treatment of Cisplatin
      injection via endobronchial ultrasound aided bronchoscopy a total of four times. Outcome
      measurements of tumor growth and survival will be compared to subjects receiving standard of
      care treatment only.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to enroll adequate number of participants
  </why_stopped>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">March 2015</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Solid Tumor Growth After Completion of Interventional Bronchoscopies</measure>
    <time_frame>18 months</time_frame>
    <description>The Organization for Research and Treatment of Cancer Response Evaluation Criteria in Solid Tumors (RECIST) system will be used to grade the response to therapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>Subjects will be followed for 5 years or the remainder of the subject's life in order to determine long-term 5 year survival rates.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>patients with limited stage SCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with limited stage SCLC treated sequentially with cisplatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Historical Controls</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>40 mg in 40 mL of normal saline for each of 4 bronchoscopies</description>
    <arm_group_label>patients with limited stage SCLC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Competent adult English speaking subjects

          -  With limited stage SCLC who have completed standard of care treatment who are
             responders with no evidence of disseminated disease other than CNS metastasis,

          -  With recurrent disseminated SCLC after standard of care treatment with symptoms
             related to central tumor obstruction,

          -  With recurrent limited stage SCLC with mediastinal/hilar recurrence not previously
             treated with intratumoral cisplatin

        Exclusion Criteria:

          -  Subjects who do not meet the inclusion criteria

          -  Subjects who, in the opinion of the investigator, are at risk undergoing a
             bronchoscopy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael A. Jantz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Florida</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 1, 2011</study_first_submitted>
  <study_first_submitted_qc>December 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2011</study_first_posted>
  <results_first_submitted>March 16, 2015</results_first_submitted>
  <results_first_submitted_qc>March 16, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 25, 2015</results_first_posted>
  <last_update_submitted>May 15, 2015</last_update_submitted>
  <last_update_submitted_qc>May 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patients With Limited Stage SCLC</title>
          <description>Subjects with limited stage SCLC treated sequentially with cisplatin.
Cisplatin: 40 mg in 40 mL of normal saline for each of 4 bronchoscopies</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patients With Limited Stage SCLC</title>
          <description>Subjects with limited stage SCLC treated sequentially with cisplatin.
Cisplatin: 40 mg in 40 mL of normal saline for each of 4 bronchoscopies</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Solid Tumor Growth After Completion of Interventional Bronchoscopies</title>
        <description>The Organization for Research and Treatment of Cancer Response Evaluation Criteria in Solid Tumors (RECIST) system will be used to grade the response to therapy.</description>
        <time_frame>18 months</time_frame>
        <population>No participants were analyzed because total enrollment numbers were too low to meet any statistical analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients With Limited Stage SCLC</title>
            <description>Subjects with limited stage SCLC treated sequentially with cisplatin.
Cisplatin: 40 mg in 40 mL of normal saline for each of 4 bronchoscopies</description>
          </group>
        </group_list>
        <measure>
          <title>Solid Tumor Growth After Completion of Interventional Bronchoscopies</title>
          <description>The Organization for Research and Treatment of Cancer Response Evaluation Criteria in Solid Tumors (RECIST) system will be used to grade the response to therapy.</description>
          <population>No participants were analyzed because total enrollment numbers were too low to meet any statistical analysis.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <time_frame>18 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Limited Stage SCLC</title>
            <description>Subjects with limited stage SCLC treated sequentially with cisplatin.
Cisplatin: 40 mg in 40 mL of normal saline for each of 4 bronchoscopies</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival</title>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Subjects will be followed for 5 years or the remainder of the subject's life in order to determine long-term 5 year survival rates.</description>
        <time_frame>5 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patients With Limited Stage SCLC</title>
            <description>Subjects with limited stage SCLC treated sequentially with cisplatin.
Cisplatin: 40 mg in 40 mL of normal saline for each of 4 bronchoscopies</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Subjects will be followed for 5 years or the remainder of the subject's life in order to determine long-term 5 year survival rates.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Patients With Limited Stage SCLC</title>
          <description>Subjects with limited stage SCLC treated sequentially with cisplatin.
Cisplatin: 40 mg in 40 mL of normal saline for each of 4 bronchoscopies</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael A. Jantz, MD</name_or_title>
      <organization>University of Florida</organization>
      <phone>352-273-8737</phone>
      <email>michael.jantz@medicine.ufl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

